Loading your page…
medRxiv
By Conway, C. R., Aaronson, S. T., Rush, A. J. and 22 others.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
In markedly treatment-resistant depression, the RECOVER trial compared the time course, extent, and durability of benefits in groups randomized to three years of active VNS (Early-Active) or one year of sham VNS followed by two years of active VNS (Delayed-Active).
For 436 participants completing month-12 (M12) assessments (Early-Active N=221; Delayed-Active N=215), longitudinal mixed-effects models characterized trajectories of benefit over 36 months in categorical outcomes pooled across blinded depressive symptom and global improvement measures. Additional analyses examined the proportions benefiting and the degree and durability of benefits.
The Early-Active group had greater odds of improvement during the RCT phase (OR=1.66; 95% CI=1.17-2.35; P=0.005). This between-group difference increased until M12 and then progressively narrowed upon VNS activation in the Delayed-Active group, approaching parity by M36. Across both groups, emergence of new beneficiaries plateaued after 24 months of active VNS, but with participants progressively achieving higher degrees of benefit thereafter. Following activation, the Delayed-Active group had significant improvement in all six categorical outcome measures. Durability was strong across depressive symptoms, function, and quality-of-life outcomes. For participants receiving active VNS throughout, durability of response was 70% from M12 to M36.
Active VNS was associated with improved benefits for both treatment groups over years 2 and 3. New beneficiaries emerged during the first two years of active VNS with continued progression to higher levels of benefit in the third year. These clinical benefits were highly durable. ClinicalTrials.gov identifier: NCT03887715.
This is a preprint: it has not been peer reviewed yet, and its findings may change.
Published in medRxiv (preprint). The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
